TherapeuticsMD Competitors
| TXMD Stock | USD 2.26 0.01 0.44% |
TherapeuticsMD vs ProMIS Neurosciences Correlation
Poor diversification
The correlation between TherapeuticsMD and PMN is 0.61 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding TherapeuticsMD and PMN in the same portfolio, assuming nothing else is changed.
Moving against TherapeuticsMD Stock
| 0.68 | P52 | NEWBURY PHARMACEUTICALS | PairCorr |
| 0.64 | 21P | Aurora Cannabis | PairCorr |
| 0.45 | VRCA | Verrica Pharmaceuticals | PairCorr |
| 0.4 | WEED | Canopy Growth Corp | PairCorr |
| 0.36 | IQ70 | 1CM INC | PairCorr |
TherapeuticsMD Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between TherapeuticsMD and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of TherapeuticsMD and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of TherapeuticsMD does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between TherapeuticsMD Stock performing well and TherapeuticsMD Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze TherapeuticsMD's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| PRPH | 8.56 | (2.76) | 0.00 | 1.12 | 0.00 | 15.47 | 77.27 | |||
| AYTU | 2.73 | 0.37 | 0.09 | 0.66 | 3.37 | 6.20 | 16.84 | |||
| BFRI | 3.65 | 0.27 | 0.07 | 0.18 | 4.19 | 9.59 | 35.60 | |||
| PHGE | 9.81 | 0.80 | 0.06 | 2.76 | 11.65 | 16.30 | 88.38 | |||
| GELS | 4.22 | (0.11) | (0.02) | 0.00 | 4.76 | 6.90 | 55.89 | |||
| EKSO | 6.42 | 1.85 | 0.30 | 1.21 | 5.14 | 11.46 | 112.11 | |||
| ERNA | 6.13 | (1.74) | 0.00 | 2.09 | 0.00 | 12.10 | 59.74 | |||
| MPLT | 3.73 | 0.59 | 0.12 | (0.94) | 3.56 | 8.28 | 39.27 | |||
| AMS | 1.29 | (0.02) | (0.03) | 0.05 | 1.34 | 3.81 | 8.10 | |||
| PMN | 5.00 | 1.51 | 0.21 | (2.27) | 5.64 | 13.32 | 35.13 |
Cross Equities Net Income Analysis
Compare TherapeuticsMD and related stocks such as ProPhase Labs, Aytu BioScience, and Biofrontera Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PRPH | (700 K) | (2.7 M) | (1.1 M) | 405 K | (7.8 M) | (3.6 M) | (2.9 M) | 41.8 M | (1.7 M) | (3.1 M) | (2.1 M) | 6.3 M | 18.5 M | (16.8 M) | (53.4 M) | (48 M) | (45.6 M) |
| AYTU | (49 K) | (59.7 K) | (57.3 K) | (5.6 M) | (7.7 M) | (28.2 M) | (22.5 M) | (10.2 M) | (47.2 M) | (13.6 M) | (58.3 M) | (108.8 M) | (17.1 M) | (15.8 M) | (13.6 M) | (12.2 M) | (12.8 M) |
| BFRI | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (37.7 M) | (640 K) | (20.1 M) | (17.8 M) | (16 M) | (16.8 M) |
| PHGE | (1 K) | (1 K) | (1 K) | (1 K) | (1 K) | (1 K) | (1.9 M) | (6.4 M) | (12.7 M) | (20.6 M) | (30.1 M) | (36.2 M) | (28.3 M) | (26.2 M) | (17.7 M) | (36.2 M) | (34.4 M) |
| GELS | (375.6 K) | (375.6 K) | (375.6 K) | (375.6 K) | (375.6 K) | (375.6 K) | (375.6 K) | (375.6 K) | (375.6 K) | (375.6 K) | (648.9 K) | (3.4 M) | (3.5 M) | (3.5 M) | (6.6 M) | (6 M) | (5.7 M) |
| EKSO | (15 M) | (15 M) | (15 M) | (12.3 K) | (33.8 M) | (19.6 M) | (23.5 M) | (29.1 M) | (27 M) | (12.1 M) | (15.8 M) | (9.8 M) | (15.1 M) | (15.2 M) | (11.3 M) | (11.7 M) | (12.3 M) |
| ERNA | (4.8 M) | (3.4 M) | (995 K) | (1.1 M) | (5 M) | (7.2 M) | (2.9 M) | (1.1 M) | (259 K) | (2 M) | 11.9 M | (122.5 M) | (24.6 M) | (21.7 M) | (44.5 M) | (40.1 M) | (38.1 M) |
| MPLT | (30 M) | (30 M) | (30 M) | (30 M) | (30 M) | (30 M) | (30 M) | (30 M) | (30 M) | (30 M) | (30 M) | (30 M) | (30 M) | (55.7 M) | (77.6 M) | (69.8 M) | (73.3 M) |
| AMS | (500 K) | 506 K | 38 K | (312 K) | (952 K) | (1.5 M) | 930 K | 1.9 M | 1 M | 659 K | (7.1 M) | 194 K | 1.3 M | 610 K | 2.2 M | 2.5 M | 2.6 M |
| PMN | (1.7 M) | (2.5 M) | (2.2 M) | (2 M) | (1.5 M) | (1.5 M) | (2.6 M) | (4.8 M) | (7.5 M) | (7.4 M) | (5.7 M) | (9.7 M) | (18.1 M) | (17.5 M) | 2.8 M | 2.5 M | 2.6 M |
TherapeuticsMD and related stocks such as ProPhase Labs, Aytu BioScience, and Biofrontera Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in TherapeuticsMD financial statement analysis. It represents the amount of money remaining after all of TherapeuticsMD operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.TherapeuticsMD Competitive Analysis
The better you understand TherapeuticsMD competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, TherapeuticsMD's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across TherapeuticsMD's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
TherapeuticsMD Competition Performance Charts
Five steps to successful analysis of TherapeuticsMD Competition
TherapeuticsMD's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by TherapeuticsMD in relation to its competition. TherapeuticsMD's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of TherapeuticsMD in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact TherapeuticsMD's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to TherapeuticsMD, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your TherapeuticsMD position
In addition to having TherapeuticsMD in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Entertainment Thematic Idea Now
Entertainment
Companies from entertainment industry including show business, news and media. The Entertainment theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Entertainment Theme or any other thematic opportunities.
| View All Next | Launch |
Check out TherapeuticsMD Correlation with its peers. For information on how to trade TherapeuticsMD Stock refer to our How to Trade TherapeuticsMD Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Will Pharmaceuticals sector continue expanding? Could TherapeuticsMD diversify its offerings? Factors like these will boost the valuation of TherapeuticsMD. If investors know TherapeuticsMD will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every TherapeuticsMD data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share 0.01 | Revenue Per Share | Quarterly Revenue Growth 0.433 | Return On Assets | Return On Equity |
TherapeuticsMD's market price often diverges from its book value, the accounting figure shown on TherapeuticsMD's balance sheet. Smart investors calculate TherapeuticsMD's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since TherapeuticsMD's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between TherapeuticsMD's value and its price as these two are different measures arrived at by different means. Investors typically determine if TherapeuticsMD is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, TherapeuticsMD's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.